Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by NewAmsterdam Pharma N.V.
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 07, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
July 29, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
July 26, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
APGE
ENGN
NAMS
NAMSW
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
July 08, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
June 11, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
May 29, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
May 21, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 09, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
May 02, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.